The field of HIV biology has been galvanized by the discovery of innate APOBEC3 cytidine deaminases, which pose powerful barriers to the replication of HIV and other retroviruses. Rapid progress has been made in understanding their mode of action, intriguing regulation within cells, expanded range of retroviral targets, and the counterstrikes utilized by retroviruses against them. While scientifically fascinating, advances in APOBEC3 biology may in the future lead to new anti-viral drugs and improved lentiviral vectors for gene therapy.
Discovery of APOBEC3G
All of the primate lentiviruses, except equine infectious anemia virus, encode a viral infectivity factor (Vif) protein. HIV-1 Vif is a 23-kDa basic phosphoprotein expressed late in the retroviral life cycle. Viruses deficient in vif ( vif) cannot mount a spreading infection when produced in "nonpermissive" cells, such as primary human CD4 T cells and macrophages, the primary targets of HIV-1. Conversely, many "permissive" laboratory-adapted T cell lines support HIV-1 infection without Vif (1, 2) . The nonpermissive phenotype proved dominant in heterokaryons formed by fusing these two types of cells (3, 4) , leading to the concept that nonpermissive cells selectively express an antiviral activity that is overcome by Vif. These studies laid the groundwork for the seminal identification of this Vif-targeted antiviral factor as APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, A3G) (5) , that is effectively encapsidated in budding virions only in the absence of Vif (6, 7) .
APOBEC Cytidine Deaminases
A3G belongs to a large family of tissuespecific cytidine deaminases (8) that display RNA editing and/or DNA mutator activity (9, 10) . Two well-studied members of this enzyme family, APOBEC1 (9) and AID (activation-induced deaminase) (11) , are tandemly arranged on chromosome 12. In intestinal epithelial cells, APOBEC1 is the key component of an RNA editosome complex (12) that deaminates cytosine-6666 in mammalian apolipoprotein B mRNA, resulting in a truncated version of apoB. In germinal center B cells, AID is required for classswitch recombination and somatic hypermutation (11) . APOBEC1 and AID both can catalyze deamination of dC residues in single-stranded DNA in vitro (10, 13, 14) . Remarkably, AID has no measurable deaminase activity unless first pretreated with RNase to remove small inhibitory RNAs bound to the enzyme (15) . Uncontrolled activity of APOBEC1, AID, and perhaps other cytidine deaminases can transform cells (16, 17) . Thus, these enzymes may be subject to intracellular regulation to curtail such events.
A3G is one of a cluster of related genes found on chromosome 22 (8) . This APOBEC3 locus shows evidence of expansion by tandem duplication and unequal crossover after the genetic radiation of mice and humans. All APOBEC3 genes (A3A-H) are arranged in the same orientation. Their pattern of expression is tissue specific. A3G, 3F, and 3C are expressed in spleen, peripheral blood lymphocytes, ovary and testes while little or no A3B mRNA is detectable in these tissues (8, 18) . However, A3B, A3C and to a lesser extent A3A mRNA, is prevalent in various cancer cell lines (8) . Active APOBEC3 functions as homodimers although heterodimers can occur. The enzyme active site contains conserved zinc ligands C/HXE and PCXXC. These proteins also contain a key glutamate required for the proton shuttling during catalysis, and two key aromatic residues involved in RNA substrate binding (8) .
Mutagenesis by Virion-Incorporated APOBEC3G
A3G packaging into HIV-1 virions involves assembly with the nucleocapsid (NC) region of the Gag viral protein and possibly binding of RNA (19) (20) (21) (22) (23) (24) (25) (26) . A3G appears to selectively target singlestranded DNA (27, 28) and yields dC-to-dU mutations in the viral minus-strand DNA formed during reverse transcription (RT) (5, (29) (30) (31) (32) . These uracil-containing DNA molecules are either degraded, probably involving the action of DNA repair enzymes like uracil DNA glycosylase (33) and apurinic-apyrimidinic endonucleases, or serve as templates for the synthesis of plus-strand DNA, yielding dG-to-dA hypermutated proviruses encoding altered proteins. These events potently halt viral spread. The single-stranded specificity also accounts for the increase in mutation frequency in a 5' to 3' direction (27) . The 3' regions in the minus-strand remain single stranded for the longest time as they await plus-strand synthesis. This antiviral activity of human A3G is not confined to HIV-1 but also extends to other lentiviruses including simian immunodeficiency virus (SIV), equine infectious anemia virus (EIAV) and even the distantly related retroviruses such as murine leukemia virus (MLV) and foamy viruses (6, 29, 31, 34, 35) Other Anti-Viral APOBEC3 Proteins Intriguingly, other APOBEC3 family members also exert antiviral activity. Like A3G, A3F induces dG-to-dA transitions in viral plus-strand DNAs and its action is blocked by HIV-1 Vif (18, (36) (37) (38) . However, the two enzymes differ in their consensus sequence for mutation: A3G favors 5'-CC dinucleotides (underline denotes the site of deamination) (27, 29, 31, 32) , while A3F prefers 5'-TC (18, 36, 37) . Mutations in the A/T rich proviruses present in AIDS patients bear the footprints of both A3G and A3F action. The hypermutation specificity of A3G and A3F is governed by the C-terminal deaminase domain (39) . Human A3B also has moderate activity against HIV-1 and an A3F-like target site consensus. However, A3B is resistant to Vif (18, 40) . As noted earlier, A3B is not expressed in many of the natural cellular targets of HIV-1 and as such may not normally influence HIV-1 replication in vivo. Neither A3F nor A3B are active against MLV while A3G is (18, 41) . Thus the spectrum of viruses impaired by A3F and A3B may well be more restricted.
Vif Neutralizes APOBEC3 Proteins
Lentiviruses have evolved a remarkable counterstrike measure to neutralize A3G. Coexpression of HIV-1 Vif and A3G in transiently transfected human or monkey cell cultures results in a significant decrease in A3G protein expression (6, 7, (42) (43) (44) (45) (46) (47) . Importantly, this striking reduction in the intracellular levels of endogenous A3G also occurs in HIV-1 infected T cells (7). This Vif-induced post-transcriptional effect makes this antiviral enzyme unavailable for subsequent incorporation into progeny virions. Thus, the antiviral effect of A3G is forfeited.
Vif's action appears to involve both the accelerated degradation of A3G by the 26S proteasome and partially impaired translation of A3G mRNA (7) . Vif induces polyubiquitylation of A3G and targets it for destruction by the proteasome (45, 46) . Vif contains two key domains, one that binds to A3G and a SLQ(Y/F)LA motif for A3G degradation via the proteasome (45) . The latter is similar to a conserved sequence in the BC-box of the suppressors of cytokine signaling (SOCS) proteins. Vif recruits an E3 ligase complex of elongins B and C, Cul5, and Rbx1 (47) . Binding of Vif to Elongin C depends on the SLQ(Y/F)LA motif in Vif and two conserved cysteines (48) and is negatively regulated by serine phosphorylation in the BC-box motif (49) . The introduction of dominant-negative mutants of Cul5, which block modification by Nedd8 or assembly with Rbx1, prevent the degradation of A3G and restore its antiviral activity (47) . Vif also induces proteasomal degradation of A3F (36) (37) (38) 50) .
Further mechanistic insights have been gleaned from inter-species studies. In contrast to the broad action of A3G, the viral protection conferred by Vif appears highly species specific (6), For example, although Vif from the SIV of African green monkey (SIVagm) triggers the degradation of its own host's A3G, it fails to neutralize human or chimpanzee A3G. Similarly, HIV-1 Vif does not impair the action of corresponding African green monkey or rhesus macaque A3G. These species-specific effects are likely key to the species tropisms of retroviruses and may thwart many cross-species transmissions.
Remarkably, this apparent species specificity is regulated by a single amino acid at position 128 in A3G (aspartic acid in human A3G and lysine in agm A3G) (51) (52) (53) (54) . Interestingly, the Vif protein of SIV from rhesus macaque (SIVmac), and possibly sooty mangabey (SIVsm), is able to neutralize A3G orthologs that occur in most of other species including human (6, 54) , a compelling correlation with the fact that SIVsm was zoonotically transmitted to humans and gave rise to HIV-2.
Although the available data argue that Vifinduced degradation of A3G plays a key role, several groups have proposed that Vif might also physically exclude A3G from virions by sequestering it from sites of viral budding (6, 42) . Moreover, the intracellular depletion of A3G and rescue of viral infectivity might be functionally separable activities of Vif (49, 55) . For example, infectious HIV viruses can be produced by cells where Vif only moderately alters the steady state levels of A3G (55) . The S144A mutation in Vif, which prevents phosphorylation at this site, compromises infectivity of progeny virions but retains the ability to induce A3G degradation (49) . This result suggests that Vif phosphorylation may regulate another as yet unidentified function of Vif that is also important for conferring full viral infectivity. Such ancillary actions of Vif deserve continued investigation.
Counterstrikes by Other Susceptible Viruses
While the lentiviral Vif protein efficiently fends off A3G and A3F, other retroviruses have evolved different escape mechanisms. Several APOBEC3 proteins potently inhibit the infectivity of viral vectors based on primate foamy viruses (PFV). The packaging of APOBEC3 into PFV virions induces dG dA hypermutations in PFV reverse transcripts. PFV Bet appears to function as the foamy virus analogue of HIV-1 Vif preventing the incorporation of the human A3G/3F proteins into progeny virions. However, Bet does not deplete human A3G/3F in virion producer cells (35) . Similar findings have emerged in studies of a distantly related feline foamy virus (FFV) (34) . Another example is provided by MLV, which replicates and spreads effectively in murine APOBEC3-positive cells yet does not encode a vif-or a bet-like gene. In this case, the MLV Gag protein has evolved to lack binding, and hence virion packaging, of the cognate murine APOBEC3. However, MLV infectivity is still restricted by certain heterologous APOBEC3 proteins that retain the ability to interact with MLV Gag (41, 56) . The lentivirus EIAV, also devoid of a Vif but sensitive to human A3G, may have evolved yet another mechanism for evading the A3G orthologs that occur in its natural hosts. It may replicate in cells lacking the enzyme, but an occult Vif-like activity or a Gag protein invisible to the deaminase cannot be excluded. EIAV, similar to feline immunodeficiency virus, also encodes a dUTPase that may provide a separate pathway to protect the virus from the effects of deamination.
APOBEC3G Restricts HIV-1 Post-Entry in Resting CD4 T Cells
How can Vif virions from permissive cells infect nonpermissive cells laden with cytoplasmic A3G but escape its potential antiviral effects? The answer emerged in studies of the cellular A3G protein. A3G exists in two different-sized forms-an enzymatically active low-molecularmass (LMM) and an inactive high-molecular-mass (HMM) ribonucleoprotein complex. In cells susceptible to HIV infection, such as H9 T cells, A3G is sequestered in an inactive HMM complex that is unable to block replication of incoming virions. Vif targets this HMM A3G complex for polyubiquitylation by recruitment of key E3 ligase components, including Cul5 and Elongin B (57).
Strikingly, A3G exists exclusively in the LMM form in peripheral blood-derived resting CD4 T cells and monocytes (57) , both of which are refractory to HIV-1 infection (58-62). LMM A3G is subsequently converted to a HMM complex when resting CD4 T cells are activated or when monocytes are induced to differentiate into macrophages. This change correlates with an increase in the susceptibility of these cells to HIV-1 infection. When expression of the LMM form in resting CD4 T cells was "knocked down" by RNA interference, the block to HIV-1 infection was greatly relieved (57) . These findings unveil a novel anti-viral function of LMM A3G as a potent post-entry restriction factor for HIV-1 in peripheral blood-derived resting CD4 T cells and likely in freshly isolated monocytes.
RT intermediates of incoming virions may be substrates for the active LMM A3G. Alternatively, LMM A3G, through its RNA binding properties (8) , may target genomic RNA-primer tRNA complexes and impair the RT reaction, leading to a kinetic delay in the accumulation of late RT products, which can be rescued by siRNAmediated knockdown of LMM A3G (57) . Only low levels of dG-to-dA hypermutations are detected in the reverse transcripts of resting CD4 T cells (57) . Thus, A3G-restricting activity may not depend strictly on deamination.
Anti-HIV-1 activity also persists for select A3G mutants lacking enzymatic activity (63) . These mutants were altered in the C-terminal active sites but retained active N-terminal sites that might be sufficient to mediate RNA binding. Several questions remain. How does the LMM A3G complex block HIV-1 infection in resting CD4 T cells? Is it analogous to the way that A3G mutants lacking cytidine deaminase activity impair HIV infection? Can the restricting activity of LMM A3G be recapitulated in cells already harboring HMM A3G by expression of A3G variants that cannot be recruited into HMM complex? Since the RT block in resting CD4 T cells is not completely relieved by siRNAmediated knockdown and A3G-and A3F-signature hypermutations are detectable in a minor portion of the viral cDNA sequences in resting CD4 T cells (57) , are other APOBEC3 members also regulated in the same manner as A3G and can they similarly participate in the post-entry restriction block encountered in resting CD4 Tcells?
After virion incorporation, A3G massively mutates nascent viral DNA form during RT. But how is A3G incorporated into virions? Assembly of A3G with viral Gag (19) (20) (21) (22) (23) (24) (25) (26) or genomic HIV-1 RNA (20, 22) appears important. Do these factors promote release of A3G from the cellular HMM complex and lead to its incorporation as a fully active LMM enzyme complex? Alternatively, A3G might be incorporated as an inactive HMM complex perhaps bound to and inactivated by HIV-1 genomic RNA. In this case, some mechanism for intravirion activation of A3G must be operational.
Other Exogenous APOBEC3 Targets
The action of APOBEC3 on reverse transcripts suggested that these enzymes might also attack other retroelements. Hepatitis B virus (HBV), the prototypic member of the hepadnavirus family, is a major cause of liver disease worldwide. Like the retroviruses, hepadnaviral replication involves RT of a pregenomic RNA (pgRNA) intermediate within nucleocapsids in the cytoplasm of virus producer cells. Both human A3G and A3F interfere with the HBV life cycle in a cotransfected Huh7 hepatoma cell line (64, 65) . A3G/3F appears to block the incorporation of HBV RNA into the subgenomic particles, destablize the viral RT complex and preclude HBV DNA accumulation in virions.
Cytidine deaminase activity appears dispensable (64) . The same phenomenon prevails in the HepG2 hepatoma cell line, but APOBEC3-mediated editing is in fact detectable in a minority of the HBV DNAs (66) (67) (68) (69) . Although APOBEC's precise antiviral mechanism against HBV requires further investigation, it seems to parallel the postentry restricting function of A3G against HIV, which may not be strictly dependent on cytidine deamination.
The deaminase-independent antiviral activity of A3G also targets HTLV-1 (70) . A3G packaged into HTLV-1 particles can reduce infectivity of HTLV-1 particles (70) although the effects were more modest when compared to HIV-1 (71) . Signature mutations, however, do not accumulate at significant levels (70) . HTLV-1 preferentially infects activated CD4 T cells that express key receptors for viral entry and thus may bypass the post-entry restricting activity of LMM A3G present in resting CD4 T cells.
Roles beyond Blocking Exogenous Retroelements
Considering their affinity for single-stranded DNA, the APBOEC3 proteins might also act on endogenous retroelements. These elements, which correspond to long interspersed nuclear elements (LINEs), short interspersed nuclear elements (SINEs), and long terminal repeat (LTR) retrotransposons, are present at high copy number in ancestral genomes and have contributed as a major driving force to genome evolution (72) . Most retroelements have lost replication competence, but some, including murine intracisternal A-particle (IAP) and MusD s e q u e n c e s , r e m a i n m o b i l e t h r o u g h retrotransposition, an intracellular process involving RT intermediates. Both human and murine A3Gs markedly inhibit retrotransposition of IAP and MusD elements (73) and even the yeast Ty1 LTR retrotransposon (74, 75) 
in vitro.
Cytidine deaminase activity appears critical for this inhibition (73, 75) . Indeed, the mouse genome contains many retrotransposon proviruses that harbor mutations consistent with APOBEC3-mediated editing (73) . In addition, studies on the genetic variability of primate APOBEC family members have revealed that these genes have been subject to strong positive selection throughout the history of primate evolution (76, 77) . This selection appears more ancient than the modern lentiviruses, suggesting that this family of genes may have expanded to prevent genome instability caused by endogenous retroviruses (77) . Surprisingly, LINE-1 (L1) non-LTR retrotransposons do not seem to be affected by A3G (73, 78) . This could reflect the nuclear localization of its RT intermediates. Nonetheless, the effect of APOBEC3 proteins on non-LTR retroelements requires careful evaluation: their replication cycle involves cytoplasmic RNA intermediates, and the APOBEC3 proteins are competent for RNA binding (8) . Furthermore, the relatively narrow tissue distribution of the APOBEC3 proteins in immune cells and germ line cells (8) raises the intriguing possibility of a natural editing substrate essential for the function of these cells or the presence of harmful elements in these cells that must be controlled. These findings argue that significant effort should be aimed at identifying the "natural" cellular targets of APOBEC3 proteins.
APOBEC3 as New Therapeutic Targets
Insights into the mechanism by which Vif counteracts A3G have revealed promising new targets for anti-HIV-1 drug development. In principle, the optimal strategy would be to identify small-molecule inhibitors that selectively disrupt the association of Vif with the A3G/3F proteins. Other interventions might include blocking recruitment of the E3 ligase by Vif. By suppressing Vif's activity, these drugs would free the endogenous A3G/3F proteins to mount their potent antiviral action against HIV-1.
Additional information concerning the factors that regulate the level of APOBEC3 expression might also provide a means to counteract the Vifmediated degradation. A3G is present at low levels in resting T cells but is strongly induced when these cells are activated by phytohemagglutinin and IL-2 (7). PMA stimulation of H9 T cells activates A3G gene transcription involving the MAP kinase signaling pathway (79) . Identifying the signaling pathways involved in induction of APOBEC3 expression might be therapeutically valuable if APOBEC3 levels could be safely boosted beyond the capacity of Vif.
The discovery that cellular LMM A3G functions as a post-entry restriction factor in resting CD4 T cells (57) could prompt evaluation of approaches to produce this active restricting activity or prevent the natural inactivation of this activity in cells that are normally highly permissive for HIV-1 infection. The conversion of LMM to HMM A3G after T cell activation merits careful assessment regarding the range of signals and the molecular pathways capable of inducing this response. Cytokines (e.g., IL-2, IL-4, IL-7 and IL-15) may confer permissivity for HIV-1 infection in resting T cells (80, 81) . Thus, cytokine stimulation could promote the assembly of A3G into the latent HMM complexes as they create a permissive state for HIV-1 in resting T cells in the absence of full-fledged cellular activation and proliferation. It will be important to determine whether cytokine-treatment of T cells can also upregulate expression of A3G and whether the increasing A3G levels is required for the assembly of HMM complexes.
Another important future task will be to define the protein and RNA cofactors that form the enzymatically inactive HMM A3G complex (57) . It remains unclear whether these HMM complexes correspond to the A3G-containing cytoplasmic bodies that lack vimentin cages (82) . Smallmolecule inhibitors blocking HMM A3G complex formation might be valuable, as this host proteinprotein interface would not be expected to undergo rapid sequence variation like Vif. A putative mutant of A3G constitutively residing in the LMM complex, even upon T cell stimulation, would also provide the cells with early intracellular resistance against incoming viruses. However, an effect of such disassembled forms of A3G on host genomic DNA must be excluded in these activated and often proliferating cellular hosts. In this respect, it will be of great value to decipher whether a LMM but catalytically inactive A3G could also mediate the post-entry block. For lentivirus vectormediated gene therapy in T cells, stimuli promoting the HMM A3G complexes formation without potentially promoting cell activation or differentiation could form a crucial step toward the successful development of therapeutic strategies for a variety of diseases including cancers.
The role of APOBEC3 members in HBV infection is unclear: APOBEC3 expression has not been demonstrated in human hepatocytes, the primary target for HBV. Interferons inhibit HBV replication by mediating noncytopathic HBV clearance in vivo and in liver cell lines (83) . That this protection seems inducible raises the possibility that a specific APOBEC family member is upregulated in hepatocytes by interferons and in turn facilitates HBV clearance. A better understanding of the potential participation of APOBEC3 in this response could facilitate the identification of new therapeutic strategies for HBV.
Concluding Remarks
HIV-1 RT is vulnerable to lethal editing by virion-incorporated host A3G cytidine deaminase. Unfortunately, the HIV-1 Vif protein circumvents this potent antiviral defense. HIV-1 also encounters a powerful post-entry restriction block mediated by the LMM form of A3G present in resting CD4 T cells. This new restricting activity of A3G is not strictly dependent on editing and is not antagonized by Vif as this viral protein is synthesized much later in the retroviral life cycle, and little or no Vif is present in these virions. These findings highlight the multifunctional properties of A3G as an antiviral factor acting at distinct steps along the retroviral life cycle, utilizing its inherent deaminase activity or a deaminase-independent anti-viral mechanism. Acting in concert with other family members, A3G proteins also likely function as important guardians of the integrity of the human genome through their effects on endogenous retroviruses and possibly other retroelements. 
